Drug Trial Radar · NCT06299111
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
195
Actual
Start
Sep 20, 2024
Primary completion
Mar 27, 2026
Study completion Mar 27, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions
- Venous Thromboembolism
Interventions
REGN9933Drug
Intravenous (IV) single dose administered
REGN7508Drug
IV single dose administered
PlaceboDrug
IV single dose administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of confirmed VTE per central reading center (CRC) reviewTime frame: Through Day 14
- Incidence of treatment-emergent adverse event (TEAEs)Time frame: Up to Day 100
- Severity of TEAEsTime frame: Up to Day 100
Locations
23 sites in 6 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Sylvester Comprehensive Cancer Center
Miami, Florida
Brigham and Women's Hospital
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Mount Sinai Medical Center
New York, New York
Memorial Sloan Kettering
New York, New York
Sveta Sofia Hospital
Sofia, Bulgaria
Juravinski Hospital
Hamilton, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
Lakeridge Health
Oshawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Hadassah University Medical Center
Jerusalem, Israel
Lanadio Medical Center
Netanya, Israel
Rabin Medical Center
Petah Tikva, Israel
Sheba Medical Center
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Shaare Zedek Medical Center
Jerusalem, Jerusalem, Israel
Soroka University Medical Center
Beersheba, Southern District, Israel
Arensia Research Clinic
Bucharest, Romania
Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca
Cluj-Napoca, Romania
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
University hospital Southampton
Southampton, Hampshire, United Kingdom
Cardiff and Vale University Health Board - University Hospital Wales
Cardiff, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.